Neurotherapeutic implications of brain-immune interactions

Neuropsychopharmacology

Volumn 39, Issue 1, 2014, Pages 242-243

  Felger, Jennifer C ^a,b   Miller, Andrew H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 4; METHYL CPG BINDING PROTEIN 2; PLACEBO; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; C-REACTIVE PROTEIN RECEPTOR, HUMAN; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTERIOR CINGULATE; ANXIETY DISORDER; ASTROCYTE; AUTISM; BASAL GANGLION; BRAIN; COGNITION; CYTOKINE RELEASE; DISEASE COURSE; GENE EXPRESSION; GLUCONEOGENESIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGY; LIPID METABOLISM; MACROPHAGE; MENTAL DISEASE; METABOLIC SYNDROME X; MICROGLIA; MOOD DISORDER; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; RETT SYNDROME; SCHIZOPHRENIA; SHORT SURVEY; T LYMPHOCYTE; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER, TREATMENT-RESISTANT; MENTAL DISORDERS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; MENTAL DISORDERS; NEUROGENESIS; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890446023     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.213     Document Type: Short Survey

References (6)

1. Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR et al (2010). Regulation of learning and memory by meningeal immunity: A key role for IL-4. J Exp Med 207: 1067-1080
2. Derecki NC, Cronk JC, Lu Z, Xu E, Abbott SB, Guyenet PG et al (2012). Wild-Type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484: 105-109
3. Mehta D, Raison CL, Woolwine BJ, Haroon E, Binder EB, Miller AH et al (2013). Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav Immun 31: 205-215
4. Miller AH, Haroon E, Raison CL, Felger JC (2013). Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depress Anxiety 30: 297-306
5. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 70: 31-41
6. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N et al (2006). Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 9: 268-275